Saudi Arabia Over the Counter (OTC) Drugs Market Size, Share & Forecast Report 2026–2034

Market Overview

The Saudi Arabia over the counter (OTC) drugs market size reached USD 1,738.7 Million in 2025. The market is projected to expand significantly, with expectations to reach USD 2,743.4 Million by 2034. This growth is driven by rising healthcare awareness, an emerging trend of self-medication, and an increasing prevalence of chronic diseases, alongside a widening retail pharmacy network, favorable government policies encouraging OTC drug sales, and rising disposable incomes across the Kingdom. The forecast period spans 2026-2034, with a compound annual growth rate (CAGR) of 5.20%. Cough, cold and flu products lead by product type, the oral route dominates by route of administration, and online pharmacies represent one of the fastest-growing distribution channels.

How AI and Technology is Reshaping the Future of Saudi Arabia Over the Counter (OTC) Drugs Market:

• AI-powered symptom checkers and virtual consultation tools are helping Saudi consumers self-select appropriate OTC remedies for everyday ailments, with the Kingdom's first AI-powered virtual clinic in Al Ahsa signaling how digital diagnostics are beginning to influence self-medication decisions nationwide.
• E-pharmacy platforms operating across Saudi Arabia are increasingly deploying AI-driven personalized product recommendation engines, guiding consumers toward suitable analgesics, cold and flu remedies, or dermatology products based on purchase history and stated symptoms, streamlining the online OTC buying journey.
• Saudi Arabia's Vision 2030 digital health agenda continues to expand AI-enabled telehealth and inventory-forecasting systems used by pharmacy chains, helping retailers anticipate demand for OTC categories across the Northern and Central, Western, Eastern, and Southern regions and reduce stock-outs.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-over-the-counter-drugs-market/requestsample

Market Growth Factors

Rising self-medication and growing health consciousness are the primary drivers of the Saudi Arabia over the counter (OTC) drugs market. A cross-sectional study conducted in Western Saudi Arabia surveyed 200 participants on their attitudes toward OTC medications, finding that most respondents were aware of potential drug interactions while a majority favored stricter OTC sales regulations. Public health campaigns, digital health resources, and easy access to online medical information are encouraging Saudi nationals to take a more proactive approach toward managing minor ailments such as cold, flu, pain, and digestive issues. As affordability and convenience continue to outweigh the need for a physician visit for everyday health concerns, demand for OTC products across pharmacies and e-commerce platforms is expected to keep climbing steadily.

Government support and regulatory reforms are providing strong structural momentum to the market. The Saudi Food and Drug Authority (SFDA) has worked extensively to simplify approval pathways and strengthen the safety and availability of OTC drugs, and has been recognized internationally for achieving an advanced maturity rating in medicines and vaccines regulation, becoming the first authority in the Eastern Mediterranean region to reach this benchmark. This regulatory credibility is reinforcing consumer trust in locally available OTC products. Vision 2030's broader healthcare agenda is also encouraging faster product registrations and easier market entry, reducing the burden on hospitals and clinics by empowering consumers to safely manage minor health issues through OTC alternatives, thereby supporting sustained industry expansion.

Market Segmentation

Product Type Insights:

• Cough, Cold and Flu Products
• Analgesics
• Dermatology Products
• Gastrointestinal Products
• Vitamins, Minerals and Supplements (VMS)
• Weight-loss/Dietary Products
• Ophthalmic Products
• Sleeping Aids
• Others

Route of Administration Insights:

• Oral
• Parenteral
• Topical
• Others

Dosage Form Insights:

• Tablets and Capsules
• Liquids
• Ointments
• Others

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Regional Insights:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Recent Development & News

February 2025: Sudair Pharma announced the establishment of a new insulin production plant in Sudair City, planning to manufacture millions of insulin pens annually and cover hundreds of thousands of patients in its first year of operation. Backed by partnerships with major global pharmaceutical manufacturers, the initiative localizes insulin production and reduces reliance on imports, reinforcing the Kingdom's position as a regional pharmaceutical hub, a development that is expected to have positive spillover effects on the broader OTC and self-care drug landscape.

March 2025: Avalon Pharmaceuticals, a Saudi-based pharmaceutical manufacturer, announced the launch of its fourth manufacturing facility, focused on producing complex medications including oncology and injectable drugs. The expansion supports the Kingdom's localization goals for pharmaceutical manufacturing and strengthens domestic production capacity, a trend that is gradually extending to OTC-focused manufacturing lines as local players scale up operations to meet rising consumer demand.

May 2025: Saudi Arabia launched the world's first AI-powered virtual doctor clinic in Al Ahsa, developed in collaboration with Synyi AI and Almoosa Health Group. The initiative reflects the Kingdom's broader push toward AI-enabled digital healthcare delivery, a shift that is expected to influence how consumers research symptoms and select appropriate OTC remedies before turning to a pharmacy or e-pharmacy platform.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302